CCO Independent Conference Coverage
CCO Independent Conference Coverage of the 2008 ICAAC/IDSA Annual Meeting*
October 25-28, 2008 | Washington, DC
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Timing and Choice of First-Line Antiretroviral Therapy
|
Track 1 of 6
|
|
|
|
   |
- Joel E. Gallant, MD, MPH
- W. David Hardy, MD
- Kathleen E. Squires, MD
|
|
|
Management of Treatment-Experienced Patients
|
Track 2 of 6
|
|
|
|
   |
- Eric S. Daar, MD
- Joseph J. Eron, Jr., MD
- Kimberly Y. Smith, MD, MPH
|
|
|
Clinical Complications of HIV and Its Therapy
|
Track 3 of 6
|
|
|
|
   |
- Judith S. Currier, MD, MSc
- Donald P. Kotler, MD
- William G. Powderly, MD
|
|
|
Hepatitis and Opportunistic Coinfections
|
Track 4 of 6
|
|
|
|
   |
- Richard E. Chaisson, MD
- Sally Hodder, MD
- Bruce Polsky, MD
|
|
|
Overview of the 2008 ICAAC/IDSA Annual Meeting
|
Track 6 of 6
|
Expert Highlights
Antiretroviral Therapy in Treatment-Naive Patients
Now Playing...
Anton L. Pozniak, MD, FRCP, reports on the 96-week results from the CASTLE, ARTEMIS, and HEAT clinical trials in treatment-naive patients as well as several analyses on the use of abacavir in patients with high HIV-1 RNA
Management of Treatment-Experienced Patients
Now Playing...
Sharon L. Walmsley, MSc, MD, FRCPC, reports on several analyses from clinical trials that inform on the assessment of activity of antiretroviral agents in treatment-experienced patients and the optimal construction of regimens for these patients.
Treatment of TB in HIV-Infected Patients
Now Playing...
Sally Hodder, MD, reviews a promising study of TMC207, an investigational drug for treatment of tuberculosis, and also reports disappointing results of a study of isoniazid treatment in children in South Africa.
Antiretroviral Resistance and Viral Tropism
Now Playing...
Daniel R. Kuritzkes, MD, discusses new data on raltegravir mechanism of action, resistance to integrase inhibitors, viral tropism, and prevalence of the K65R mutation in populations with subtype C virus.
Timing and Choice of First-Line Antiretroviral Therapy
Now Playing...
Joel E. Gallant, MD, MPH, reports on the phase III STARTMRK trial of raltegravir vs efavirenz in antiretroviral-naive patients and on the NA-ACCORD cohort study on when to start antiretroviral therapy.
New Agents
Now Playing...
Joseph J. Eron, Jr., MD, describes new data on the investigational maturation inhibitor bevirimat and entry inhibitor PRO 140 and discusses the reanalysis of data from the MERIT trial.
Initiating Antiretroviral Therapy
Now Playing...
Eric S. Daar, MD, gives an overview of several trials of antiretroviral-naive patients and discusses new information that may inform on when to start therapy.
Treatment-Experienced Patients
Now Playing...
Paul E. Sax, MD, reviews real-world trials of newer agents in the treatment of antiretroviral patients
Metabolic Complications of HIV and ART
Now Playing...
William G. Powderly, MD, discusses interesting data on bone metabolism from the SMART study and several key papers about diabetes in HIV-infected patients.
Treatment of Hepatitis Coinfection
Now Playing...
Bruce Polsky, MD, discusses the use of fixed-dose tenofovir/emtricitabine for the treatment of HIV/HBV-coinfected patients and the failure of high ribavirin doses to provide increased ribavirin exposure when given with erythropoietin.
Mouse over thumbnails for more information on the segments
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
HIV-1 RNA Suppression With Tenofovir/Emtricitabine vs Abacavir/Lamivudine in First-Line Boosted PI-Based HAART in Systematic Review of 12 Studies
Systematic review of 12 trials suggests higher rates of virologic suppression with tenofovir/emtricitabine vs abacavir/emtricitabine when combined with atazanavir/ritonavir, fosamprenavir/ritonavir, or lopinavir/ritonavir, but analysis unable to account for discontinuations due to suspected abacavir hypersensitivity in the era before the availability of HLAB*5701 screening
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|